Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07847359 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial

Name: Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial — clinical trial record (NCT07847359)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Cryo-IA-Check

StatusRecruiting

PhasePhase 2

SponsorSun Yat-sen University

Started2026-10-01

View on ClinicalTrials.gov ↗

Sun Yat-sen University

609 trials monitored

See 13 trials at risk

Melanoma

1,020 trials monitored

See 45 trials at risk

To explore the efficacy and safety of cryoablation combined with hepatic arterial infusion of iparomlimab and tuvonralimab, intravenous dacarbazine, and oral lenvatinib in patients with liver metastases from malignant melanoma.

Trial Details

NCT Number	NCT07847359
Lead Sponsor	Sun Yat-sen University
Conditions	Melanoma (Skin) Stage IV
Enrollment	28 participants
Start Date	2026-10-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-29